SLC5A2 and stroke disorder: In the multivariable adjustment model (Model 3), compared to empagliflozin, the risk of developing HF, MI, AP, stroke, and AF did not differ between dapagliflozin, canagliflozin, and other SGLT2 inhibitors (Fig. 2).